We are live on ! Find out more
SCMP

Sucampo Pharmaceuticals, Inc.
SCMP

Delisted

SCMP was delisted on the 12th of February, 2018.

167 hedge funds and large institutions have $272M invested in Sucampo Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 68 increasing their positions, 46 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

170% more call options, than puts

Call options by funds: $1.97M | Put options by funds: $730K

48% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 46

0% more funds holding

Funds holding: 167 → 167 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 23

0.59% less ownership

Funds ownership: 56.13% → 55.53% (-0.59%)

9% less capital inflows, than outflows

Capital inflows: $44.4M | Capital outflows: $49M

Holders
167
Holders Change
–
Holders Change %
0%
% of All Funds
4.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
23
Increased
68
Reduced
46
Closed
23
Calls
$1.97M
Puts
$730K
Net Calls
+$1.24M
Net Calls Change
+$883K

SCMP Hedge Fund Activity: Q2 2017 in Review

167 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q2 2017, worth a combined $272M — down 5.2% from $287M a quarter earlier.

Fund positioning in SCMP was balanced in Q2 2017: 23 funds opened new positions, 23 closed out, 68 added to existing stakes and 46 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $12.8M. The largest seller was Redwood Investments, exiting entirely with an estimated $6.64M sold.

  • 167 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $272M of Sucampo Pharmaceuticals, Inc. stock for Q2 2017, down 5.2% quarter-over-quarter.
  • 23 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q2 2017 and 23 closed out, a net change of 0 holders.
  • The largest Sucampo Pharmaceuticals, Inc. buyer in Q2 2017 was NEA Management Company, an estimated $12.8M added.
  • The largest Sucampo Pharmaceuticals, Inc. seller in Q2 2017 was Redwood Investments, an estimated $6.64M sold.

Based on aggregated 13F filings for Q2 2017.